SYNB1618 demonstrates dose-responsive, non-saturated increases in gastrointestinal Phe consumption, suggesting therapeutic potential for Phenylketonuria (PKU). A mechanistic model predicts SYNB1618's function in PKU patients and informs clinical development.
The company's 3D Predict assay has been validated for predicting responses to temozolomide in glioblastoma patients, with predictive accuracy comparable to its previous results in ovarian cancer. The test identifies future responders and non-responders, enabling personalized treatment strategies.
SYNB1891, an engineered E. coli Nissle strain producing cyclic di-AMP, demonstrates anti-tumor activity and generates immunological memory in preclinical models of cancer. The therapy is being evaluated in a Phase 1 clinical trial for patients with advanced solid tumors or lymphoma.
Researchers identified S15 as a major immune suppressor in B7-H1-negative tumors resistant to current anti-PD therapies. A first-in-human Phase 1/2 clinical trial is underway for NC318, a monoclonal antibody targeting S15.
Researchers have found significantly elevated levels of 4-ethylphenylsulfate (4-EPS) in serum samples from children with Autism Spectrum Disorder (ASD), suggesting a potential biomarker for the condition. Elevated 4-EPS levels were also associated with worse social performance, indicating its possible role in ASD pathology.
The study demonstrates the efficacy of a single dose of NDV-3A in reducing recurrences of vaginitis in patients with RVVC, with younger patients showing higher efficacy rates. The vaccine also generates rapid and robust immune responses.
The study published in Stroke demonstrates that neural stem cell-derived extracellular vesicles (NSC EVs) improved tissue and functional recovery in pigs following ischemic stroke. The results also showed NSC EV treatment was neuroprotective, eliminated intracranial hemorrhage, and improved behavior and mobility.
Positive data from Phase 1 trials of Nexvax2 in celiac disease demonstrate safety, tolerability, and bioactivity. The vaccine reduces gluten-specific T cells' responsiveness to antigenic stimulation without apparent duodenal injury.
A single blood test measuring glycated CD59 at week 24-28 of gestation identified women with GDM with high sensitivity and specificity. The study found that median levels of plasma GCD59 were 8.5-fold higher in women who failed the GCT and 10-fold higher in women diagnosed with GDM.
A Phase 2 clinical trial found that MLE4901 reduced the number and severity of hot flushes by 73% compared to placebo. The treatment was well-tolerated, with no serious adverse events reported. This study demonstrates the potential for MLE4901 as a non-hormonal treatment option for menopausal hot flushes.
Researchers develop protocol to efficiently grow cochlear progenitor cells into large colonies with high capacity for differentiation, offering potential treatment for hearing loss. The approach, leveraging Wnt signaling and histone deacetylase inhibition, enables regeneration of sensory hair cells in multiple mammalian species.
Researchers at Caltech discovered a novel link between the gut microbiome and Parkinson's disease, finding that gut bacteria promote hallmark pathology, neuroinflammation, and motor dysfunction. The study suggests targeting the gut microbiome may provide a new approach for diagnosing and treating PD.
Researchers at Adimab isolated a broad panel of neutralizing anti-Ebola virus antibodies from a survivor of the 2014 outbreak. The study highlights the speed and effectiveness of Adimab's single B cell isolation platform, which was able to identify over 300 monoclonal antibodies within weeks of receiving a blood sample.
DeuteRx has discovered a method for in vivo stabilization and differentiation of thalidomide analogs, improving anti-inflammatory and antitumorigenic properties. The company's 'deuterium-enabled chiral switching' platform enables the testing and development of single enantiomers with improved therapeutic properties.
Researchers at Gilead Sciences and Beryllium published structural data on HCV polymerase during RNA replication, shedding light on the NS5B catalytic mechanism. This information will be useful in identifying replication inhibitors of other pathogenic viruses in the Flaviviridae family.
The DAPT Study found that continuing dual antiplatelet therapy for at least 30 months significantly reduced the risk of stent thrombosis and major adverse cardiovascular events. This benefit was observed across all stent types and patient characteristics, with a notable reduction in heart attack risk.
Researchers used large-scale patient data analytics to predict future risk of metabolic syndrome, identifying individual variable impact on risk associated with adherence to prescribed medications and routine doctor visits. The study also found that improving waist circumference and blood glucose yielded the largest benefits.
Researchers have engineered a series of molecules with the potential to treat most neurodegenerative diseases, including Alzheimer's, Parkinson's, and Huntington's. The GAIM-changing molecules recognize characteristic common to many toxic misfolded proteins and can prevent new aggregates from forming while clearing existing ones.
Researchers discovered a novel clot structure involving polyhedrocytes in contracted clots, making them less responsive to medications. T2HemoStat enabled the detection of this unique structure, which could lead to better diagnostic tools and therapeutic choices.
Researchers demonstrate rapid and sensitive identification of specific Candida species directly from whole blood using T2Candida, reducing mortality rate to 11%. The breakthrough approach enables fast detection in approximately three hours, outperforming current gold standard methods.
STX209 treatment corrects core aspects of FXS pathophysiology, improving social function in patients. The drug has the potential to significantly improve lives of patients with fragile X syndrome and may also have a positive effect on autism spectrum disorders.
A Phase I/II study demonstrated the experimental norovirus VLP vaccine significantly reduces the incidence of gastroenteritis due to norovirus, with a 47% reduction compared to placebo. The vaccine also increased antibody titers and functional responses in subjects, indicating increased protection against illness.
A recent study published in PNAS reveals the unique role of EZH2 enzyme in cancer, facilitating the development of selective small molecule therapeutics for specific forms of human lymphomas. The research highlights the importance of targeting HMTs in genetically-defined cancer patients with high unmet needs.
Researchers at Emerald BioStructures have developed new allosteric small molecule modulators of phosphodiesterase-4 (PDE4) with improved safety and efficacy. These discoveries validate the company's structure-based drug design capabilities for addressing previously undruggable targets in inflammatory diseases and cognitive impairments.
The company has developed a 2-week method for generating human induced-pluripotent stem cells with a 200-fold increase in yield. This breakthrough has broad implications for pharmaceutical-grade iPSCs production without genetic modification at commercial scale.